Analysts Expect Akari Therapeutics PLC (AKTX) to Post -$1.00 Earnings Per Share

Wall Street brokerages expect Akari Therapeutics PLC (NASDAQ:AKTX) to announce ($1.00) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Akari Therapeutics’ earnings. Akari Therapeutics posted earnings of ($0.08) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 1,150%. The company is scheduled to report its next quarterly earnings results on Friday, March 30th.

On average, analysts expect that Akari Therapeutics will report full year earnings of ($2.00) per share for the current year. For the next financial year, analysts expect that the business will report earnings of ($3.00) per share. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Akari Therapeutics.

Akari Therapeutics (NASDAQ:AKTX) last released its quarterly earnings data on Monday, November 13th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.00) by $0.91.

A number of research firms have weighed in on AKTX. Zacks Investment Research lowered Akari Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 16th. ValuEngine upgraded Akari Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, November 30th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $7.50.

An institutional investor recently raised its position in Akari Therapeutics stock. Hikari Power Ltd raised its position in Akari Therapeutics PLC (NASDAQ:AKTX) by 152.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 151,334 shares of the biopharmaceutical company’s stock after buying an additional 91,322 shares during the period. Hikari Power Ltd owned about 1.28% of Akari Therapeutics worth $929,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 21.04% of the company’s stock.

Akari Therapeutics (AKTX) opened at $3.16 on Monday. The firm has a market capitalization of $48.36, a PE ratio of -1.18 and a beta of -8.64. Akari Therapeutics has a 52 week low of $3.13 and a 52 week high of $22.20.

ILLEGAL ACTIVITY NOTICE: “Analysts Expect Akari Therapeutics PLC (AKTX) to Post -$1.00 Earnings Per Share” was first posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.

Get a free copy of the Zacks research report on Akari Therapeutics (AKTX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply